Bioactive Collagen Peptides have been classified as safe by international authorities such as the European Food Safety Authority (EFSA) (Ex. Link EFSA) and the US Food and Drug Administration (FDA) (Ex. Link FDA). Various clinical studies and meta-analyses have shown that the frequency and type of adverse effects of collagen peptides are similar to those of tested placebos [Liu et al. 2017, Van Vijen et al. 2012, Bruyère et al. 2012, McAlindon et al. 2011, Moskowitz 2000].
In clinical studies, every report of adverse effects is recorded and documented regardless of possible associations. Therefore, you find records of adverse effects even under therapy with a placebo. Only later will the causality between reported adverse effect and test product or placebo be evaluated and classified as either not given, unlikely, possible, or probable.
Adverse Effects Documented in Relation to Bioactive Collagen Peptides
There is a comprehensive review about adverse effects of collagen peptides presented by Moskowitz. In this study, 278 of 389 participants reported adverse effect, with 137 cases in the group with Bioactive Collagen Peptides and 141 cases in the placebo group. 32 in the intervention group and 29 in the placebo group were classified as possible or probable related to the study medication. The recorded adverse effects that were classified as probably associated with the use of Bioactive Collagen Peptides included three cases of flatulence, one of nausea, and one of digestive problems. In both groups, the adverse effects classified as possible were mainly attributed to the gastrointestinal tract and manifested as flatulence, diarrhoea, nausea, and digestive problems. Their severity was evaluated as low or moderate, and no severe adverse effects were observed.
Following studies and meta-analyses with an observation period of up to 12 months also found no significant differences in frequency and type of adverse effects between the Bioactive Collagen Peptides group and the placebo group. In summary, long-term administration of Bioactive Collagen Peptides seems to be safe, although it should be noted that long-term data collection is still warranted.
Last update: August 2022